COMMUNIQUÉS West-GlobeNewswire

HUTCHMED Announces Sovleplenib Granted US FDA Orphan Drug Designation for Autoimmune Hemolytic Anemia
05/11/2026
— Eligible for development incentives including 7 years of US market exclusivity upon regulatory approval — — Marks the second US FDA Orphan Drug Designation for sovleplenib, following its recent designation for primary [...]
TaiMed Biologics to Present 24-Week Phase 2a Data on TMB-365/TMB-380 Maintenance Regimen at HIV Glasgow 2026
05/11/2026
Company will present results from a Phase 2a study of TMB-365/TMB-380 administered every eight weeks as maintenance therapy in virologically suppressed people living with HIV-1, along with an encore poster on its Phase [...]
Use Of Ryoncil First Line After Steroids For Pediatric Acute Graft Versus Host Disease Highlighted In Key Opinion Leader Webinar
05/11/2026
NEW YORK, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced that it hosted a key opinion leader webinar this [...]
Step Pharma to present data from ongoing phase 2 clinical trial of dencatistat in essential thrombocythaemia at 68th ASH Annual Meeting
05/11/2026
First presentation of clinical data from ET programme demonstrating a consistent and clinically meaningful platelet control with favourable tolerability profile VECTRA trial will enrol up to 50 participants with high- [...]
Cloudbreak Pharma Announces Top-Line Results from its Phase 3 Study of CBT-001 in Patients with Pterygium
05/11/2026
Both doses of CBT-001 demonstrated statistically significant improvements in conjunctival hyperemia at Month 3 versus vehicle (p<0.001), with improvement observed as early as Week 2 and maintained through Month 12 [...]
Revolution Medicines Reports Third Quarter 2026 Financial Results and Update on Corporate Progress
04/11/2026
Received U.S. FDA approval and launched RASONQUE ® (daraxonrasib) for adult patients with metastatic pancreatic cancer who have received at least one prior systemic therapy or who are not candidates for multiagent [...]
Agomab to Participate in Upcoming Investor Conferences
04/11/2026
Antwerp, Belgium, November 4, 2026 – Agomab Therapeutics NV (Nasdaq: AGMB) (“Agomab”), a clinical-stage biopharmaceutical company focused on fibro-inflammation, today announced that members of the management team will [...]
Tenaya Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
04/11/2026
Received Regenerative Medicine Advanced Therapy (RMAT) Designation from U.S. FDA for TN-401 Gene Therapy for PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy TN-201 and TN-401 Program Updates on Upcoming [...]
LeMaitre Q3 2026 Financial Results
04/11/2026
BURLINGTON, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq: LMAT), a provider of vascular devices, implants, and services, today reported Q3 2026 results, announced a quarterly dividend of $0. [...]
Myriad Genetics Reports Third Quarter 2026 Financial Results; Raises Mid-Point of Full-Year 2026 Revenue Guidance Following Solid Execution Definitive Agreement to Sell Prenatal Health Business to Support Strategic Growth Initiatives
04/11/2026
Highl ights Third quarter 2026 revenue was $202.7 million, representing a 6% sequential increase and a 1% decrease year-over-year. Higher Cancer Care Continuum (CCC) product mix and continued progress on payer [...]
PacBio Announces Third Quarter 2026 Financial Results
04/11/2026
MENLO PARK, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended September 30, 2026. Recent Business Highlights Delivered total revenue of $40.6 million [...]
Sight Sciences Reports Third Quarter 2026 Financial Results and Raises Full-Year 2026 Revenue Guidance
04/11/2026
MENLO PARK, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, [...]
Mineralys Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
04/11/2026
– Commercialization plans for lorundrostat are on track ahead of PDUFA target date of December 22, 2026 – – New analyses from the pivotal Launch-HTN trial showed 46% of participants with uncontrolled or resistant [...]
Adaptive Biotechnologies Reports Third Quarter 2026 Financial Results
04/11/2026
SEATTLE, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive [...]
PROCEPT BioRobotics Reports Third Quarter 2026 Financial Results and Reaffirms 2026 Financial Guidance
04/11/2026
SAN JOSE, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics ® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions [...]
Vaxcyte Reports Third Quarter 2026 Financial Results and Provides Business Update
04/11/2026
VAX-31 Adult Indication: Announced Positive Topline Data from OPUS-1 Pivotal Phase 3 Trial; VAX-31 Met All Prespecified Primary Endpoints, Was Well Tolerated and Demonstrated a Safety Profile Similar to PCV20 and PCV21 [...]
Clover Health Reports Third Quarter 2026 Results
04/11/2026
Business Highlights: Strong third quarter performance brings year-to-date GAAP Net Income to $62 million alongside 49% year-over-year Medicare Advantage membership growth Improved Full Year 2026 guidance across all [...]
Larimar Therapeutics to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference
04/11/2026
BALA CYNWYD, Pa., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced [...]
Relay Therapeutics Reports Third Quarter 2026 Financial Results and Corporate Updates
04/11/2026
Phase 3 ReDiscover-2 trial in 2L breast cancer expected to complete enrollment in mid-2027 Updated data from ongoing Phase 1/2 ReInspire trial of zovegalisib in vascular anomalies to be featured in oral presentation at [...]

Pages